Literature DB >> 16896663

Auger radiation targeted into DNA: a therapy perspective.

Franz Buchegger1, Florence Perillo-Adamer, Yves M Dupertuis, Angelika Bischof Delaloye.   

Abstract

BACKGROUND: Auger electron emitters that can be targeted into DNA of tumour cells represent an attractive systemic radiation therapy goal. In the situation of DNA-associated decay, the high linear energy transfer (LET) of Auger electrons gives a high relative biological efficacy similar to that of alpha particles. In contrast to alpha radiation, however, Auger radiation is of low toxicity when decaying outside the cell nucleus, as in cytoplasm or outside cells during blood transport. The challenge for such therapies is the requirement to target a high percentage of all cancer cells. An overview of Auger radiation therapy approaches of the past decade shows several research directions and various targeting vehicles. The latter include hormones, peptides, halogenated nucleotides, oligonucleotides and internalising antibodies. DISCUSSION: Here, we will discuss the basic principles of Auger electron therapy as compared with vector-guided alpha and beta radiation. We also review some radioprotection issues and briefly present the main advantages and disadvantages of the different targeting modalities that are under investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896663     DOI: 10.1007/s00259-006-0187-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  116 in total

1.  Systemic radionuclide therapy in pain palliation.

Authors:  Knut Liepe; Roswitha Runge; Jörg Kotzerke
Journal:  Am J Hosp Palliat Care       Date:  2005 Nov-Dec       Impact factor: 2.500

2.  Further clinical evaluation of 2'-deoxy-5-fluorouridine (NSC-27640).

Authors:  W L Wilson; H F Bisel; E T Krementz; R C Lien; J V Prohaska
Journal:  Cancer Chemother Rep       Date:  1967-04

3.  Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen.

Authors:  F J Primus; R H Wang; D M Goldenberg; H J Hansen
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

4.  Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.

Authors:  G Mariani; S Di Sacco; R Bonini; L Di Luca; S Buralli; D Bonora; S Ricci; J Baranowska-Kortylewicz; S J Adelstein; A Falcone; A I Kassis
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

5.  Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors.

Authors:  J Mester; K DeGoeij; M Sluyser
Journal:  Eur J Cancer       Date:  1996-08       Impact factor: 9.162

6.  The evolving role of alemtuzumab in management of patients with CLL.

Authors:  S Faderl; S Coutré; J C Byrd; C Dearden; A Denes; M J S Dyer; S A Gregory; J G Gribben; P Hillmen; M Keating; S Rosen; P Venugopal; K Rai
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

7.  In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.

Authors:  Roisin M Dwyer; Elizabeth R Bergert; Michael K O'connor; Sandra J Gendler; John C Morris
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

8.  Contributions of nuclear medicine to the therapy of malignant tumors.

Authors:  L E Feinendegen
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.

Authors:  M Hosono; M N Hosono; F Kraeber-Bodéré; A Devys; P Thédrez; M Fiche; E Gautherot; J Barbet; J F Chatal
Journal:  J Nucl Med       Date:  1998-09       Impact factor: 10.057

Review 10.  Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

Authors:  Marion de Jong; Dik Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-05       Impact factor: 9.236

View more
  39 in total

1.  Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter.

Authors:  Maryline Gardette; Janine Papon; Mathilde Bonnet; Nicolas Desbois; Pierre Labarre; Ting-Dee Wu; Elisabeth Miot-Noirault; Jean-Claude Madelmont; Jean-Luc Guerquin-Kern; Jean-Michel Chezal; Nicole Moins
Journal:  Invest New Drugs       Date:  2010-06-22       Impact factor: 3.850

2.  Photofragmentation of halogenated pyrimidine molecules in the VUV range.

Authors:  Mattea Carmen Castrovilli; Paola Bolognesi; Antonella Cartoni; Daniele Catone; Patrick O'Keeffe; Anna Rita Casavola; Stefano Turchini; Nicola Zema; Lorenzo Avaldi
Journal:  J Am Soc Mass Spectrom       Date:  2014-01-03       Impact factor: 3.109

3.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

Review 4.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 5.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

6.  Evaluation of aromatic radiobromination by nucleophilic substitution using diaryliodonium salt precursors.

Authors:  Dong Zhou; Sung Hoon Kim; Wenhua Chu; Thomas Voller; John A Katzenellenbogen
Journal:  J Labelled Comp Radiopharm       Date:  2017-06-14       Impact factor: 1.921

7.  Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic.

Authors:  Eftychia Koumarianou; Tatiana A Slastnikova; Marek Pruszynski; Andrey A Rosenkranz; Ganesan Vaidyanathan; Alexander S Sobolev; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-04-02       Impact factor: 2.408

8.  Targeted Brain Tumor Radiotherapy Using an Auger Emitter.

Authors:  Giacomo Pirovano; Stephen A Jannetti; Lukas M Carter; Ahmad Sadique; Susanne Kossatz; Navjot Guru; Paula Demétrio De Souza França; Masatomo Maeda; Brian M Zeglis; Jason S Lewis; John L Humm; Thomas Reiner
Journal:  Clin Cancer Res       Date:  2020-02-17       Impact factor: 12.531

9.  Molecular targeting of intracellular compartments specifically in cancer cells.

Authors:  Hetal Pandya; Denise M Gibo; Waldemar Debinski
Journal:  Genes Cancer       Date:  2010-05

10.  Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases.

Authors:  Georgios S Limouris; Achilles Chatziioannou; Dimitrios Kontogeorgakos; Dimitrios Mourikis; Maria Lyra; Panagiotis Dimitriou; Anastasia Stavraka; Athanassios Gouliamos; Lambros Vlahos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.